|
Volumn 5, Issue 2, 2010, Pages 65-66
|
New FDA safety warnings for LABAs: A call for asthma guidelines revisit for solo beta agonist
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALLERGEN;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
CORTICOSTEROID;
IRRITANT AGENT;
LONG ACTING DRUG;
SHORT ACTING DRUG;
ASTHMA;
CLINICAL TRIAL;
DISEASE CONTROL;
DISEASE EXACERBATION;
DRUG LABELING;
DRUG SAFETY;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
HEALTH HAZARD;
HUMAN;
LONG TERM CARE;
MONOTHERAPY;
MORTALITY;
PATIENT COMPLIANCE;
PRACTICE GUIDELINE;
RISK BENEFIT ANALYSIS;
|
EID: 77956029068
PISSN: 18171737
EISSN: 19983557
Source Type: Journal
DOI: 10.4103/1817-1737.62468 Document Type: Editorial |
Times cited : (5)
|
References (7)
|